Biopharma Funding Contracted Last Year – And 2023 Will See The Squeeze Continue

Up To 300 Companies Could Seek New Funds This Year

 
• By Andrew McConaghie
  
Scrip Perspectives 2023
After the boom years of 2020 and 2021, the environment turned difficult for many early-stage biotechs last year, and 2023 could be even more challenging. • Source: Shutterstock

More from Business

More from Scrip